Axovant Sciences Ltd (AXON) Receives $13.61 Consensus Target Price from Brokerages

Shares of Axovant Sciences Ltd (NASDAQ:AXON) have been assigned an average rating of “Hold” from the fifteen brokerages that are covering the company, MarketBeat reports. Four equities research analysts have rated the stock with a sell recommendation, five have given a hold recommendation and six have assigned a buy recommendation to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $13.61.

A number of research analysts have commented on the stock. BidaskClub downgraded shares of Axovant Sciences from a “hold” rating to a “sell” rating in a research note on Saturday, December 2nd. HC Wainwright reiterated a “buy” rating and set a $11.00 price objective on shares of Axovant Sciences in a research note on Friday, December 1st. Oppenheimer reiterated a “hold” rating on shares of Axovant Sciences in a research note on Sunday, November 12th. Piper Jaffray Companies restated a “hold” rating on shares of Axovant Sciences in a research report on Friday, November 10th. Finally, Zacks Investment Research downgraded shares of Axovant Sciences from a “buy” rating to a “hold” rating in a research report on Thursday, November 9th.

Several institutional investors have recently bought and sold shares of the company. Wells Fargo & Company MN lifted its position in shares of Axovant Sciences by 1.6% in the 2nd quarter. Wells Fargo & Company MN now owns 22,790 shares of the biotechnology company’s stock worth $528,000 after buying an additional 355 shares during the last quarter. Legal & General Group Plc increased its holdings in shares of Axovant Sciences by 20.2% in the 2nd quarter. Legal & General Group Plc now owns 6,955 shares of the biotechnology company’s stock worth $162,000 after acquiring an additional 1,168 shares during the period. Bank of America Corp DE increased its holdings in shares of Axovant Sciences by 38.9% in the 1st quarter. Bank of America Corp DE now owns 7,396 shares of the biotechnology company’s stock worth $111,000 after acquiring an additional 2,072 shares during the period. Russell Investments Group Ltd. increased its holdings in shares of Axovant Sciences by 38.5% in the 2nd quarter. Russell Investments Group Ltd. now owns 10,041 shares of the biotechnology company’s stock worth $233,000 after acquiring an additional 2,789 shares during the period. Finally, The Manufacturers Life Insurance Company increased its holdings in shares of Axovant Sciences by 16.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 22,377 shares of the biotechnology company’s stock worth $519,000 after acquiring an additional 3,184 shares during the period. Institutional investors own 96.93% of the company’s stock.

Axovant Sciences (NASDAQ AXON) traded up $0.28 during midday trading on Thursday, reaching $5.30. Axovant Sciences has a twelve month low of $4.60 and a twelve month high of $27.98. The company has a current ratio of 5.94, a quick ratio of 5.94 and a debt-to-equity ratio of 0.34.

COPYRIGHT VIOLATION WARNING: “Axovant Sciences Ltd (AXON) Receives $13.61 Consensus Target Price from Brokerages” was first posted by Week Herald and is owned by of Week Herald. If you are accessing this news story on another site, it was illegally copied and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this news story can be read at https://weekherald.com/2017/12/10/axovant-sciences-ltd-axon-receives-13-61-consensus-target-price-from-brokerages.html.

Axovant Sciences Company Profile

Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.

Analyst Recommendations for Axovant Sciences (NASDAQ:AXON)

Receive News & Ratings for Axovant Sciences Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences Ltd and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply